Veru Inc. Files Definitive Proxy Statement
Ticker: VERU · Form: DEFA14A · Filed: Mar 22, 2024 · CIK: 863894
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting, corporate-governance
TL;DR
VERU proxy filing is out - shareholders vote soon on company matters.
AI Summary
Veru Inc. filed a Definitive Proxy Statement (DEFA14A) on March 22, 2024. This filing is a standard proxy statement, indicating it's related to shareholder voting matters, such as electing directors or approving corporate actions. The company, formerly known as Female Health Co. and Wisconsin Pharmacal Company Inc., is based in Miami, Florida, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing is crucial for shareholders as it outlines important information regarding upcoming shareholder meetings and voting procedures, allowing them to make informed decisions about the company's governance.
Risk Assessment
Risk Level: low — This is a routine DEFA14A filing, which is a standard disclosure for public companies regarding shareholder meetings and voting, and does not inherently present new risks.
Key Players & Entities
- VERU INC. (company) — Registrant
- FEMALE HEALTH CO (company) — Former Company Name
- WISCONSIN PHARMACAL COMPANY INC (company) — Former Company Name
- 20240322 (date) — Filing Date
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, or Definitive Proxy Statement, is used by companies to solicit proxy votes from shareholders for an upcoming shareholder meeting, detailing matters to be voted upon.
When was this DEFA14A filed by Veru Inc.?
Veru Inc. filed this DEFA14A on March 22, 2024.
What industry does Veru Inc. operate in?
Veru Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Has Veru Inc. always been known by its current name?
No, Veru Inc. was formerly known as Female Health Co. and prior to that, Wisconsin Pharmacal Company Inc.
Where is Veru Inc. headquartered?
Veru Inc. is headquartered in Miami, Florida, with its business address at 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, FL 33127.
Filing Stats: 1,560 words · 6 min read · ~5 pages · Grade level 19.6 · Accepted 2024-03-22 16:51:55
Filing Documents
- d811179ddefa14a.htm (DEFA14A) — 21KB
- g811179g0322123407196.jpg (GRAPHIC) — 2KB
- 0001193125-24-075394.txt ( ) — 26KB
Forward-Looking Statements
Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, express or implied statements related to whether and when the planned phase 2b trial of enobosarm discussed above will commence or produce topline data or patients will progress into the extension study, the planned design, timing, endpoints, patient population and patient size of such trial and whether such trial will successfully meet any of its endpoints, whether enobosarm will enhance weight loss or preserve muscle in, or meet any unmet need for, obesity patients and whether it will enhance weight loss, whether the Company will be successful in its transformation into a late stage biopharmaceutical company focused on obesity and oncology, the expected timing of the Companys completion and filing of restated financial statements and the net effect of such restatement on the Companys historical financial opportunity, plan, predict, potential, estimate, should, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based upon current plans and strategies of the Company and reflect the Companys current assessment of the risks and uncertainties related to its business and are made as of the date of this press release. The Company assumes no obligation to update any forward- looking statements contained in this press release because of new information or future events, developments or circumstances. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties mater